In a retrospective EHR cohort spanning 2015–2024, Stanford Health Care identified 181 patients with epilepsy treated with clobazam oral soluble film, including a 29-patient Lennox-Gastaut syndrome (LGS) subset. LGS patients were younger on average (13.6 years vs. 21.1 years), more likely to have switched from clobazam tablets or suspension, and showed higher concomitant cannabidiol use than the broader epilepsy group.
The core development is Assertio’s presentation of the first real-world evidence describing utilization of Sympazan, the only FDA-approved oral film formulation of clobazam for adjunctive treatment of LGS in patients two years and older. Presented as a poster at ANA2025, the study characterizes patient demographics, medication patterns, and comorbidities rather than outcomes or safety. It is a single-center, retrospective new-user analysis using routine-care EHR data and does not attempt to demonstrate efficacy or comparative effectiveness.
Strategically, this is a positioning move. With generic clobazam tablets and suspensions entrenched, the oral film must compete on administration advantages and practical fit in pediatric and cognitively impaired populations where dysphagia and caregiver logistics drive adherence. Generating RWE that maps who is prescribed the film, under what circumstances, and alongside which co-therapies is a logical precursor to payer discussions and guideline influence. The signal that LGS patients are switching in from other clobazam forms points to a conversion narrative that Assertio can lean into, while the higher cannabidiol co-use highlights a real-world regimen pattern that requires dose and interaction management—an operational point of differentiation if the company can codify best practices.
For clinicians and sites, the dataset reinforces what many see in practice: LGS populations skew younger, need flexible administration, and often sit on polytherapy that includes cannabidiol. That combination raises well-known pharmacokinetic considerations with clobazam that can increase exposure and sedation risk, suggesting the utility of standardized monitoring and dose-adjustment protocols in clinics and specialty pharmacies. For payers, the single-center description of switching behavior and co-medication patterns is a starting point, not an endpoint; broader claims-linked analyses on persistence, rescue-med utilization, and caregiver-reported burden will be needed to justify formulary positioning above generics. For sponsors and CROs, the study is a reminder that formulation lifecycle strategies are increasingly underpinned by pragmatic EHR-based cohorts rather than traditional trials, and that single-site datasets can seed but not settle market access debates. Vendors in data aggregation and safety surveillance may see an opportunity in expanding this into a multi-institution RWE program that captures outcomes and resource use.
What to watch next is whether Assertio converts this utilization snapshot into evidence on adherence, persistence, discontinuation drivers, and clinical outcomes such as seizure frequency, hospitalization, and rescue medication reliance. A multi-site, claims/EHR-linked analysis with matched comparators (film versus tablet/suspension) would materially advance the case with payers and guidelines. Pharmacovigilance detail on cannabidiol–clobazam co-therapy, including titration patterns and adverse event rates, would also resonate with prescribers managing polytherapy. The main risks are study generalizability, selection bias inherent to single-center retrospective designs, and the absence of outcomes data—limitations that will cap the impact of this first release. If the company follows with broader RWE and pragmatic protocolized switching studies, Sympazan’s differentiation could move from a convenience narrative to operational value in LGS care pathways.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
